Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 136, Issue 2, Pages 476-486
Publisher
Wiley
Online
2014-06-03
DOI
10.1002/ijc.29007
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive Tumors
- (2013) Mahiuddin Ahmed et al. PLoS One
- Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
- (2012) M. Klinger et al. BLOOD
- Phase II trial of hu14.18-IL2 for patients with metastatic melanoma
- (2012) Mark R. Albertini et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Trifunctional Bispecific Antibodies Induce Tumor-Specific T Cells and Elicit a Vaccination Effect
- (2012) Nina Eissler et al. CANCER RESEARCH
- Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission
- (2012) Nai-Kong V. Cheung et al. JOURNAL OF CLINICAL ONCOLOGY
- Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model
- (2012) Peter Ruf et al. Journal of Translational Medicine
- Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma
- (2012) B. D. Choi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Towards a universal disulphide stabilised single chain Fv format: importance of interchain disulphide bond location and vL-vH orientation
- (2012) E. E. Weatherill et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo
- (2012) Nai-Kong V. Cheung et al. OncoImmunology
- Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
- (2011) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells
- (2011) Jerome Thiery et al. NATURE IMMUNOLOGY
- Genotypes of NK Cell KIR Receptors, Their Ligands, and Fc Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy
- (2010) D. C. Delgado et al. CANCER RESEARCH
- Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR
- (2010) Jennifer S. Michaelson et al. mAbs
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
- (2010) Alice L. Yu et al. NEW ENGLAND JOURNAL OF MEDICINE
- T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells
- (2010) Ralf Lutterbuese et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Reducing Epitope Spread during Affinity Maturation of an Anti-Ganglioside GD2 Antibody
- (2009) J. Hu et al. JOURNAL OF IMMUNOLOGY
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
- (2008) R. Bargou et al. SCIENCE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now